Polypharmacy and Drug Interactions in the COVID-19 Pandemic.

The COVID-19 pandemic generated a great impact on health systems. We compared evolution, polypharmacy, and potential drug-drug interactions (P-DDIs) in COVID-19 and non-COVID-19 hospitalizations during first wave of pandemic. Prescriptions for hospitalized patients ≥ 18 years (COVID-19 and non-COVID-19 rooms) between April and September 2020 were included. The computerized medical decision support system SIMDA and the physician order entry system Hdc.DrApp.la were used. Patients in COVID-19 rooms were divided into detectable and non-detectable, according to real-time reverse transcription polymerase chain reaction (RT-PCR). Number of drugs, prescribed on day 1, after day 1, and total; polypharmacy, excessive polypharmacy, and P-DDIs were compared. 1,623 admissions were evaluated: 881 COVID-19, 538 detectable and 343 non-detectable, and 742 non-COVID-19. Mortality was 15% in COVID-19 and 13% in non-COVID-19 (RR [non-COVID-19 vs. COVID-19]: 0.84 [95% CI] [0.66-1.07]). In COVID-19, mortality was 19% in detectable and 9% in non-detectable (RR: 2.07 [1.42-3.00]). Average number of drugs was 4.54/patient (SD ± 3.06) in COVID-19 and 5.92/patient (±3.24) in non-COVID-19 (p<0.001) on day 1 and 5.57/patient (±3.93) in COVID-19 and 9.17/patient (±5.27) in non-COVID-19 (p<0.001) throughout the hospitalization. 45% received polypharmacy in COVID-19 and 62% in non-COVID-19 (RR: 1.38 [1.25-1.51]) and excessive polypharmacy 7% in COVID-19 and 14% in non-COVID-19 (RR: 2.09 [1.54-2.83]). The frequency of total P-DDIs was 0.31/patient (±0.67) in COVID-19 and 0.40/patient (±0.94) in non-COVID-19 (p=0.022). Hospitalizations in the COVID-19 setting are associated with less use of drugs, less polypharmacy and less P-DDIs. Detectable patients had higher mortality.

Development and Implementation of the Hdc.DrApp.la and SIMDA Programs to Reduce Polypharmacy and Drug-drug Interactions in Patients Hospitalized in Internal Medicine.

OBJECTIVES: We evaluated polypharmacy and possible drug-drug interactions (p-DDIs) in hospitalized patients before and after using the SIMDA Computerized Medical Decision Support System (CMDSS). MATERIALS AND METHODS: We included the prescriptions of ≥ 18 years hospitalized patients in the internal medicine department. We developed and implemented the Hdc.DrApp Physician Order Entry System and the CMDSS SIMDA, which detects p-DDIs and signals dosage adjustment based on renal function. To evaluate the impact of the CMDSS, we made a comparison Before (Survey) / After (Intervention): Survey between Oct/22/2019, and Mar/21/2020, and Intervention between Apr/4/2020 and Sep/3/2020. We analyze prescriptions from the first day and after the first day. We compared the number of drugs, polypharmacy (≥ 5 drugs), excessive polypharmacy (≥ 10 drugs), and p-DDIs. We evaluated differences with the X2 test, Yates correction, Fisher's exact test, ANOVA, and post hoc tests according to their characteristics. RESULTS: We evaluated 2,834 admissions: Survey 1,211 and Intervention 1,623. The number of drugs per patient was 6.02 (± 3.20) in Survey and 5.17 (± 3.22) in Intervention (p < 0.001) on the first day and 9.68 (± 5.60) in Survey and 7.22 (± 4.93) in Intervention (p < 0.001) throughout the hospitalization. Polypharmacy was present in 64% of the Survey and 53% of Interventions (RR: 0.83 (0.78-0.88); and excessive polypharmacy in 14% of the Survey and 10% of Intervention (RR: 0.73, 0.60-0.90). The frequency of total p-DDIs was 1.91/patient (± 4.11) in Survey and 0.35 (± 0.81) in the Intervention (p < 0.001). CONCLUSIONS: We developed and implemented the Hdc.DrApp and SIMDA systems that were easy to use and allowed us to quantify and reduce polypharmacy and p-DDIs.

Miocardiopatía arritmogénica. Genes y proteínas desmosómicas / Arrhythmogenic Cardiomyopathy. Genes and Desmosomal Proteins

RESUMEN Desde 1996 esta enfermedad figura en la clasificación de las miocardiopatías de la OMS con el nombre de "miocardiopatía arritmogénica". A fines de la década del 70 se estableció que el ventrículo derecho (VD) puede ser el sustrato para el desarrollo de arritmias. En la década del 80 se describió el reemplazo del miocardio por tejido fibroadiposo y su naturaleza hereditaria. Posteriores descubrimientos permitieron la identificación de varios genes implicados en la producción de proteínas desmosómicas que participan en el acoplamiento intercelular lo cual llevó a definir a la miocardiopatía arritmogénica como una enfermedad desmosómica. El electrocardiograma y el ecocardiograma resultaron fundamentales y la angiocardiografía invasiva se utilizó para detectar disquinesia-aquinesia y aneurismas del VD. La biopsia endomiocárdica se perfiló como el gold standard para el diagnóstico, debido a su capacidad para detectar el reemplazo transmural por tejido fibroadiposo. El advenimiento de la resonancia magnética cardíaca (RMC) con realce tardío de gadolinio ha permitido revelar no solamente anomalías morfológico-funcionales sino también daño tisular. El conocimiento de la estructura del disco intercalar, involucrado en el acoplamiento intercelular ha permitido determinar que no solamente los desmosomas estarían comprometidos, sino que habría varias proteínas constituyentes tanto de los desmosomas, como de las uniones adherentes, las uniones gap, y los canales iónicos, integradas en una unidad conocida como "área composita". Ésta constituye una amalgama entre elementos de sostén y canales iónicos que participan en la propagación del potencial de acción, lo que ha permitido desarrollar el concepto de disco intercalar compuesto por los llamados "nodos excitoadhesivos". Las implicancias clínicas en el desarrollo de arritmias malignas son obvias.

ABSTRACT In 1996 this disease was introduced into the WHO classification of cardiomyopathies with the term "arrhythmogenic cardiomyopathy". By the end of the 70s the right ventricle (RV) was identified as a substrate for the development of arrhythmias. The replacement of the myocardium by fibrofatty tissue and the hereditary nature of this condition were described in the 1980s. Later findings led to the identification of several genes involved in the production of desmosomal proteins participating in intercellular coupling, which led to defining arrhythmogenic cardiomyopathy as a desmosomal disease. Electrocardiography and echocardiography are fundamental tools, and invasive angiocardiography was used to detect dyskinesia-akinesia and right ventricular aneurysms. Endomyocardial biopsy was established as the gold standard for the diagnosis due to its ability to detect transmural replacement by fibrofatty tissue. The advent of cardiac magnetic resonance imaging (CMRI) with late gadolinium enhancement reveals morphological and functional abnormalities and tissue damage. The understanding of intercalated disc structure involved in intercellular coupling has made it possible to determine that, apart from desmosomes, several desmosomal proteins, as adherens junctions, gap junctions and ion channels are integrated into a unit known as the " area composita". The area composita constitutes an amalgam between supporting elements and ion channels that participate in action potential propagation, which has led to develop the concept that intercalated discs are constituted by "adhesion/ excitability nodes". The clinical implications in the development of malignant arrhythmias are obvious.

Bretschneider Solution and Two Antianginal Drugs Protect Peripheral Tissue in an Animal Model of Hemorrhagic Shock.

ABSTRACT: Shock and subsequent resuscitation provoke ischemia-reperfusion injury. Trimetazidine (TMZ), allopurinol (ALO), and histidine-tryptophan-ketoglutarate (HTK) solution, can protect from ischemia-reperfusion injury in chronic coronary syndromes and in transplantation. The objective of the current study is to compare, in a hemorrhagic shock and standard resuscitation animal model, organ damage parameters between placebo and treatment with TMZ, ALO, or HTK. Shock was induced in Wistar rats by controlled arterial bleeding, maintaining mean arterial pressure between 38 and 42 mm Hg for 60 minutes; then, drawn blood was reinfused. Animals were divided into: Sham (n = 4), Control (n = 6), TMZ (n = 7), ALO (n = 9), and HTK (n = 7). At the end of the experiment, animals were sacrificed and tissue harvested. TMZ, ALO and HTK decreased histopathologic damage in heart [Control: 1.72 (1.7-1.77); TMZ: 1.75 (1.72-1.79); ALO: 1.75 (1.74-1.8); HTK: 1.82 (1.78-1.85); all P < 0.05], kidney [Control: 3 (2-3); TMZ: 1 (1-2); ALO: 1 (1-1); HTK: 1(1-1); all P < 0.05] and intestine [Control: 3 (2-3); TMZ: 1 (1-2); ALO: 1 (1-1); HTK: 1 (0-2); all P < 0.05]. Also, treatment with TMZ, ALO, and HTK increased immunohistochemical expression of thioredoxin-1 in heart [Control: 6.6 (5.6-7.4); TMZ: 9.5 (8.1-9.7); ALO: 9.1 (8.4-10.2); HTK: 14.2 (12.6-15); all P < 0.05]; and kidney [Control: 4.6 (4-5.1); TMZ: 9.7 (9.3-9.9); ALO: 9.6 (9-9.9); HTK: 16.7 (16.1-17); all P < 0.05]. In an experimental model of hemorrhagic shock, TMZ, ALO, and HTK solution attenuated cell damage in multiple parenchyma and increased antioxidant defenses.

Telmisartan for treatment of Covid-19 patients: An open multicenter randomized clinical trial.

Background: Angiotensin receptor blockers (ARBs), such as telmisartan, have been postulated to treat Covid-19-induced lung inflammation. Methods: This is a parallel-group, randomized, two-arm, open-label, adaptive, multicenter superiority trial with 1:1 allocation ratio. Participants included patients from 18 years of age hospitalized with Covid-19 with 4 or fewer days since symptom onset enrolled at a university and a community hospital in Buenos Aires, Argentina. Exclusion criteria included prior intensive care unit (ICU) admission and use of ARBs/angiotensin converting enzyme inhibitors at randomization. Control arm received standard care alone and treatment arm telmisartan 80 mg twice daily for 14 days. Primary outcomes were C-reactive protein (CRP) plasma levels at day 5 and 8 after randomization. Secondary outcomes included time to discharge within 15 days, admission to ICU and death at 15- and 30-days. NCT04355936 (Completed). Findings: A pragmatic decision to end the study before the third interim analysis was made on Oct. 30th due to sharp reduction in recruitment. A total of 162 patients were randomized. 158 patients enrolled between May 14 and October 30 2020, were included in the analysis, 80 in the standard care and 78 in the telmisartan added to standard care group. Baseline absolute CRP serum levels were 5.53 ± 6.19 mg/dL (95% CI 6.91 to 4.15, n = 80) and 9.04 ± 7.69 (95% CI 9.04 to 10.82, n = 74) in the standard care and telmisartan added to standard care groups, respectively. Day 5 control-group CRP levels were 6.06 ± 6.95 mg/dL (95% CI 7.79-4.35, n = 66) while telmisartan group were 3.83 ± 5.08 mg/dL (95% CI 5.08-2.59, n = 66, p = 0.038). Day 8 CRP levels were 6.30 ± 8.19 mg/dL (95% CI 8.79-3.81, n = 44) and 2.37 ± 3.47 mg/dL (95% CI 3.44-1.30, n = 43, p = 0.0098) in the control and telmisartan groups, respectively (all values expressed as mean ± SD). Kaplan-Meier analysis showed that telmisartan-treated patients had a lower median time-to-discharge (control=15 days; telmisartan=9 days). Death by day 30 was reduced in the telmisartan-treated group (control 22.54%, 16/71; telmisartan 4.29%, 3/70 participants; p = 0.0023). Composite ICU, mechanical ventilation or death was reduced by telmisartan treatment at days 15 and 30. No adverse events were reported. Interpretation: Our study suggests that the ARB telmisartan, a widely used antihypertensive drug, is safe and could reduce morbidity and mortality in hospitalized patients infected with SARS -CoV-2 by anti-inflammatory effects. Further studies employing telmisartan are needed for confirmation of our results and to define its true therapeutic value as a tool against Covid-19.

Structural changes in endocrine pancreas of male Wistar rats due to chronic cola drink consumption. Role of PDX-1.

AIM: The objective of this work was to analyze the structural changes of the pancreatic islets in rats, after 6 month consuming regular and light cola for 6 months. Also, we have analyzed the possible role of PDX-1 in that process. Finally, with the available knowledge, we propose a general working hypothesis that explains the succession of phenomena observed. Previously, we reported evidence showing that chronic cola consumption in rats impairs pancreatic metabolism of insulin and glucagon and produces some alterations typically observed in the metabolic syndrome, with an increase in oxidative stress. Of note It is worth mentioning that no apoptosis nor proliferation of islet cells could be demonstrated. In the present study, 36 male Wistar rats were divided into three groups to and given free access to freely drink regular cola (C), light cola (L), or water (W, control). We assessed the impact of the three different beverages in on glucose tolerance, lipid levels, creatinine levels and immunohistochemical changes addressed for the expression of insulin, glucagon, PDX-1 and NGN3 in islet cells, to evaluate the possible participation of PDX-1 in the changes observed in α and ß cells after 6 months of treatment. Moreover, we assessed by stereological methods, the mean volume of islets (Vi) and three important variables: the fractional ß -cell area, the cross-sectional area of alpha (A α-cell) and beta cells (A ß-cell), and the number of ß and α cell per body weight. Data were analyzed by two-way ANOVA followed by Bonferroni's multiple t-test or by Kruskal-Wallis test, then followed by Dunn's test (depending on distribution). Statistical significance was set at p<0.05. Cola drinking caused impaired glucose tolerance as well as fasting hyperglycemia (mean:148; CI:137-153; p<0.05 vs W) and an increase of in insulin immunolabeling (27.3±19.7; p<0.05 vs W and L). Immunohistochemical expression for PDX-1 was significantly high in C group compared to W (0.79±0.71; p<0.05). In this case, we observed cytoplasmatic and nuclear localization. Likewise, a mild but significant decrease of in Vi was detected after 6 months in C compared to W group (8.2±2.5; p<0.05). Also, we observed a significant decrease of in the fractional ß cell area (78.2±30.9; p<0.05) compared to W. Accordingly, a reduced mean value of islet α and ß cell number per body weight (0.05±0.02 and 0.08±0.04 respectively; both p<0.05) compared to W was detected. Interestingly, consumption of light cola increased the Vi (10.7±3.6; p<0.05) compared to W. In line with this, a decreased cross-sectional area of ß-cells was observed after chronic consumption of both, regular (78.2±30.9; p<0.05) and light cola (110.5±24.3; p<0.05), compared to W. As for, NGN3, it was negative in all three groups. Our results support the idea that PDX-1 plays a key role in the dynamics of the pancreatic islets after chronic consumption of sweetened beverages. In this experimental model, the loss of islets cells might be attributed to autophagy, favored by the local metabolic conditions and oxidative stress.

Coronary Intimal Thickening Begins in Fetuses and Progresses in Pediatric Population and Adolescents to Atherosclerosis.

The prevalence of coronary intimal thickening (IT) was assessed in fetuses and pediatric population. We studied the coronary arteries of 63 hearts obtained from fetuses, infants, children, and adolescents, deceased from noncardiac disease or trauma. Histomorphometric analysis, planimetry, and immunohistochemical studies were conducted. Intimal thickening consisted of proliferation of smooth muscle cells and scarce monocytes embedded in amorphous deposits within the internal elastic membrane (IEM). Intermingled lesions of intimal hyperplasia and parietal nonstenotic plaques were also observed. Intimal thickening was found in 10% of 20 fetuses, in 33.3% of 18 infants, 73.3% of 15 children, and 100% of 10 adolescents. A significant correlation (r = 0.671, P < 0.001) was found between the extent of IT and age. The IEM was duplicated or interrupted in 43% of patients, showing a positive correlation with the degree of IT (P = 0.01). Intimal thickening was predominantly found near bifurcation sites in the left anterior descending coronary artery (55.6%) and in zones free of bifurcation in the right coronary artery (75%). In conclusion, the prevalence and extension of IT lesions are higher at older ages within a young population. Intimal thickening may be regarded as the first event occurring in coronary preatherosclerosis, preceding lipid deposition.

Productos intermedios de la cocaína: la pasta base o "paco" / Intermediate products of cocaine: the base paste or "paco"

El uso indebido de drogas se ha convertido en un grave problema a nivel mundial. En los últimos años, en nuestro país se ha incrementado en más del 200% el consumo de pasta base de cocaína (paco). A pesar de que el paco es un producto intermedio en la obtención de cocaína, y que muchos de sus efectos son atribuibles al contenido de esa droga, su consumo produce un cuadro clínico claramente distinto al observado en los consumidores de clorhidrato de cocaína, lo cual puede estar relacionado con su impureza. Sin perjuicio del gran impacto social producido por el consumo de paco, poco se sabe sobre su composición química y menos aún sobre sus efectos crónicos en los distintos órganos ni sobre su fisiopatología. Si bien existe material de autopsia de adictos al paco, los hallazgos están contaminados por la coexistencia en un mismo paciente de múltiples tóxicos. Urge la formación de grupos multidisciplinarios, con moderna tecnología para enfrentar este gravísimo flagelo. (AU)

Drug abuse has become a serious problem worldwide. In recent years, in our country the consumption of cocaine base paste (Paco) has increased by more than 200%. Despite of the fact that Paco is an intermediate product in the manufacture of cocaine, and that many of its effects are attributable to its content, its consumption produces a clearly different clinical picture than that observed in cocaine hydrochloride users, which It may be related to the impurity of this drug. Without prejudice to the great social impact produced by the consumption of this drug, little is known about its chemical composition and even less about its chronic effects on the different organs or its pathophysiology. Although there is an autopsy material for drug addicts, the findings are contaminated by the coexistence of multiple toxins in the same patient. The formation of multidisciplinary groups is urgent, with modern technology to face this very serious scourge. (AU)

A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy.

One of the most difficult management issues in lupus nephritis (LN) is the optimal duration of maintenance immunosuppression after patients are in clinical remission. Most patients receive immunosuppression for years, based mainly on expert opinion. Prospective data are unavailable. Complicating this issue are data that patients in clinical remission can still have histologically active LN; however, the implications of this are unknown. To study this, the Lupus Flares and Histological Renal Activity at the end of Treatment study (ClinicalTrial.gov, NCT02313974) was designed to examine whether residual histologic activity predisposes to LN flares in class III and IV LN. Patients in complete clinical remission for at least 12 months who had received at least 36 months of immunosuppression were eligible. Patients consented to a second kidney biopsy, were tapered off maintenance immunosuppression and were then followed prospectively for LN flares over 24 months. Forty-four patients were enrolled, and 36 completed the study. LN flares occurred in 11 patients, and ten of these had residual histologic activity on the second biopsy. All patients with an NIH activity index over two flared. The activity index and duration of systemic lupus erythematosus at the second biopsy were independent predictors of flare. A predictive equation based on these variables discriminated between flare and no flare with a sensitivity of 100%, specificity of 88%, and a misclassification rate of 8.3%. Thus, a repeat kidney biopsy may be useful in managing maintenance immunosuppression in LN, and patients in histologic remission may be candidates for withdrawal of therapy.

Cardiorenal Involvement in Metabolic Syndrome Induced by Cola Drinking in Rats: Proinflammatory Cytokines and Impaired Antioxidative Protection.

We report experimental evidence confirming renal histopathology, proinflammatory mediators, and oxidative metabolism induced by cola drinking. Male Wistar rats drank ad libitum regular cola (C, n = 12) or tap water (W, n = 12). Measures. Body weight, nutritional data, plasma glucose, cholesterol fractions, TG, urea, creatinine, coenzyme Q10, SBP, and echocardiograms (0 mo and 6 mo). At 6 months euthanasia was performed. Kidneys were processed for histopathology and immunohistochemistry (semiquantitative). Compared with W, C rats showed (I) overweight (+8%, p < 0.05), hyperglycemia (+11%, p < 0.05), hypertriglyceridemia (2-fold, p < 0.001), higher AIP (2-fold, p < 0.01), and lower Q10 level (-55%, p < 0.05); (II) increased LV diastolic diameter (+9%, p < 0.05) and volume (systolic +24%, p < 0.05), posterior wall thinning (-8%, p < 0.05), and larger cardiac output (+24%, p < 0.05); (III) glomerulosclerosis (+21%, p < 0.05), histopathology (+13%, p < 0.05), higher tubular expression of IL-6 (7-fold, p < 0.001), and TNFα (4-fold, p < 0.001). (IV) Correlations were found for LV dimensions with IL-6 (74%, p < 0.001) and TNFα (52%, p < 0.001) and fully abolished after TG and Q10 control. Chronic cola drinking induced cardiac remodeling associated with increase in proinflammatory cytokines and renal damage. Hypertriglyceridemia and oxidative stress were key factors. Hypertriglyceridemic lipotoxicity in the context of defective antioxidant/anti-inflammatory protection due to low Q10 level might play a key role in cardiorenal disorder induced by chronic cola drinking in rats.

Exercise Ameliorates Endocrine Pancreas Damage Induced by Chronic Cola Drinking in Rats.

PURPOSE: This study evaluates whether the daily practice of an exercise routine might protect from endocrine pancreas damage in cola drinking rats. METHODS: Forty-eight Wistar rats were randomly assigned to 4 groups depending on a) beverage consumption ad libitum, water (W) or cola beverage (C), and b) physical activity, sedentary (S) or treadmill running (R). Accordingly, 4 groups were studied: WS (water sedentary), WR (water runner), CS (cola sedentary) and CR (cola runner). Body weight, nutritional data, plasma levels of glucose, creatinine, total cholesterol and cholesterol fractions, and triglycerides (enzymocolorimetry), and systolic blood pressure (plethysmography) were measured. After 6 months, euthanasia was performed (overdose sodium thiopental). Pancreatic tissue was immediately excised and conventionally processed for morphometrical and immunohistochemical determinations. RESULTS: The effects of running and chronic cola drinking on pancreas morphology showed interaction (p<0.001) rather than simple summation. Cola drinking (CS vs WS) reduced median pancreatic islet area (-30%, 1.8 10(4) µm2 vs 2.58 10(4) µm2, p<0.0001) and median ß-cell mass (-43%, 3.81 mg vs 6.73 mg, p<0.0001), and increased median α/ß ratio (+49%, 0.64 vs 0.43, p< 0.001). In water drinking rats (WR vs WS), running reduced median α-cell mass (-48%, 1.48 mg vs 2.82 mg, p<0.001) and α/ß ratio (-56%, 0.19 vs 0.43, p<0.0001). Differently, in cola drinking rats (CR vs CS), running partially restored median islet area (+15%, 2.06 10(4) µm2 vs 1.79 10(4) µm2, p<0.05), increased median ß-cell mass (+47%, 5.59 mg vs 3.81 mg, p <0.0001) and reduced median α/ß ratio (-6%, 0.60 vs 0.64, p<0.05). CONCLUSION: This study is likely the first reporting experimental evidence of the beneficial effect of exercise on pancreatic morphology in cola-drinking rats. Presently, the increase of nearly 50% in ß cells mass by running in cola drinking rats is by far the most relevant finding. Moderate running, advisably indicated in cola consumers and patients at risk of diabetes, finds here experimental support.

Las bebidas cola aceleran el crecimiento de la placa aterosclerótica en ratones ApoE-/- / Cola Beverages Accelerate Growth of the Atherosclerotic Plaque in ApoE-/- Mice

Introducción Los hábitos de alimentación poco saludables durante la infancia y la juventud se han suge¡rido como favorecedores de las complicaciones ateroscleróticas en edades más avanzadas. El creciente consumo de bebidas cola en las últimas décadas se ha asociado con el desarrollo de obesidad e incremento en la incidencia de aterosclerosis y enfermedades cardiovasculares. A su vez, se sabe que existe correspondencia entre el consumo de estas bebidas y etapas de la vida, el cual es mayor en los niños, los adolescentes y los adultos jóvenes. Objetivo Evaluar el efecto del consumo de bebidas cola sobre la aterosclerosis. Material y métodos Se distribuyeron ratones ApoE-/- (8 semanas de edad) en tres grupos según el consumo libre de agua (A), bebida cola azucarada (C) y bebida cola edulcorada light (L). Al cabo de 8 semanas las bebidas cola se reemplazaron por agua. Los ratones fueron sacrificados secuencialmente: antes del tratamiento (8 semanas de edad) y luego de su interrupción (16, 20, 24 y 30 semanas de edad). Se extrajeron la aorta ascendente y el hígado. Se calculó la relación entre el área de la placa aórtica y el espesor de la capa media (relación placa/media). Se evaluó la inflamación del parénquima hepático según la escala de NASH. Resultados La relación placa/media varió según la bebida (F2,54 = 3,433, p < 0,04) y la edad (F4,54 = 5,009, p < 0,03) y fue mayor en los grupos C y L (p < 0,05 a las 16 y 20 semanas, p < 0,01 a las 24 y 30 semanas). La inflamación del parénquima hepático (F2,9 = 13,29, p < 0,002) y portal (F2,9 = 6,30, p < 0,02) aumentó cinco y dos veces, respectivamente, en función del tiempo (p < 0,01 y p < 0,03) entre las semanas 20 y 30, en contraste con la esteatosis y el daño hepatocelular, que no se modificaron. El grupo A (evolución natural de la aterosclerosis) se caracterizó por la aceleración del crecimiento del área de placa en paralelo con un rápido aumento de la inflamación hepática alrededor de la semana 20. Conclusiones El consumo de bebidas cola en ratones ApoE-/- entre las semanas 8 y 16 de edad aumentó la tasa de progresión de la aterosclerosis. Los datos sugieren que, en este modelo murino, el consumo sostenido de bebidas cola durante las etapas tempranas de la vida puede acelerar el agravamiento del daño aterosclerótico en etapas más tardías.(AU)

Cola Beverages Accelerate Growth of the Atherosclerotic Plaque in ApoE-/- Mice Introduction Unhealthy eating habits during childhood and youth have been suggested as predisposing factors to atherosclerotic complications later in life. The growing consumption of cola beverages in recent decades has been associated with the development of obesity and increased incidence of atherosclerosis and cardiovascular disease. We also know that there is a correspondence between the consumption of these beverages and the different stages of life, being higher in children, adolescents and young adults. Objective This study evaluates the effect of cola beverage consumption on atherosclerosis. Methods ApoE-/- mice (8 week-old) were randomized into 3 groups according to free access to water (W), sucrose sweetened carbonated cola drink (C) or aspartame-acesulfame K sweetened carbonated light cola drink (L). At 8 weeks cola beverages were switched to water. The mice were sequentially euthanized: before treatment (8 week old mice) and after treatment discontinuation (20, 24, and 30 week old mice). The ascending aorta and the liver were removed. Aortic plaque area was analyzed and plaque/media-ratio was calculated. Hepatic inflammation was assessed according to the NASH scale. Results Plaque/media-ratio varied according to drink treatment (F2,54=3.433, p <0.04) and age (F4,54=5.009, p <0.03) and was higher in the C and L groups (p <0.05 at 16 and 20 weeks, p <0.01 at 24 and 30 weeks). Hepatic parenchymal inflammation (F2,9=13.29, p <0.002) and portal inflammation (F2,9 =6.30, p <0.02) varied fivefold and twofold in contrast to steatosis and hepatocellular damage which remained unchanged throughout the study.Natural evolution of atherosclerosis in ApoE-/- mice (W group) evidenced acceleration of plaque growth in parallel with a rapid increase in hepatic inflammation around week 20 of age. Conclusions Cola beverage consumption in 8-16 week old ApoE-/- mice accelerated atherosclerosis progression. Data suggest that, in this murine model, sustained cola consumption at early stages of life may predispose to atherosclerosis progression later in life.(AU)